Oral GLP-1s: Foundayo and Wegovy Tablets, Explained

For most of the GLP-1 era, the needle was the price of entry. That has changed. Oral GLP-1 therapy is now real, branded, and FDA-approved on two fronts: Wegovy Tablets (oral semaglutide) and Foundayo (orforglipron), Eli Lilly's once-daily small-molecule GLP-1. This guide covers what the oral options are, what they cost at pharmacy pass-through, and how a clinician decides between a pill and a pen.

The oral options and their pass-through prices

At $220.40 for entry dosing, oral therapy now undercuts every injectable option on the branded pass-through price list — and remains a fraction of the roughly $1,000-plus U.S. list prices for injectable GLP-1s.

Pill or pen: how the clinical decision works

The two oral drugs are more different than they look. Oral semaglutide is a peptide: absorption is sensitive, so it comes with strict fasting and timing rules that reward disciplined routines. Orforglipron is a small molecule — no injection, no refrigeration, fewer timing constraints — which is precisely why it matters for patients who ruled out GLP-1 therapy over the needle or the logistics.

Injectables still carry the deepest trial evidence, including the largest average weight-loss results in head-to-head-era studies, and remain the default for many patients. The honest answer is that the right form is the one your biology tolerates, your life sustains, and your Biomarker Audits validate quarter over quarter. On a platform with zero medication margin, nothing pushes that decision in either direction: the membership is $299 whether the prescription is a $220 pill or a $520 pen.

The same rules as everything else on the platform

Oral GLP-1s on the GoodLife Health platform follow the same non-negotiables as the injectables: branded and FDA-approved only, never compounded; prescribed by licensed physicians of Beluga Health, P.A. under GoodLife Health's clinical protocols after comprehensive labs and contraindication screening; and billed by the pharmacy at pass-through cost. GLP-1 therapy — oral or injectable — remains one axis of cardiometabolic optimization, managed alongside hormones, thyroid, and vascular markers rather than as a standalone product.

FAQ

What oral GLP-1 medications are available? Two branded, FDA-approved options: Wegovy Tablets (oral semaglutide) at 1.5mg through 25mg, and Foundayo (orforglipron) at 0.8mg through 17.2mg — both available on the GoodLife Health platform at pharmacy pass-through pricing.

What do oral GLP-1s cost? At pass-through, Wegovy Tablets and Foundayo both start at $220.40 a month at entry doses, rising to $370.40 at higher doses — billed by the pharmacy with no markup.

What is Foundayo? Foundayo is orforglipron, Eli Lilly's once-daily oral small-molecule GLP-1 receptor agonist. As a small molecule rather than a peptide, it requires no injection, no refrigeration, and carries fewer timing constraints than oral semaglutide.

Are oral GLP-1s as effective as injections? Injectables carry the deepest trial evidence and remain the default for many patients. The right form is a clinical decision made from your labs, tolerance, and goals — and verified with quarterly Biomarker Audits rather than assumed.

Does choosing a pill change the membership fee? No. The GoodLife Health membership is a flat $299/month whether your protocol uses an oral GLP-1, an injectable, or no medication at all.

Related guides

• Branded GLP-1 pass-through prices
• The true monthly cost of GLP-1 telehealth
• Cardiometabolic optimization: the definitive guide
• Medical Weight Loss at GoodLife Health

References

1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/